# A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

Source: https://onco.cc/trials/nct06939595/  
OnCo record `nct06939595` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab in non-small-cell lung cancer, run by Celltrion, active and no longer recruiting.

## Summary

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer is a phase 3 interventional study registered as NCT06939595 by Celltrion, with 225 participants enrolled, started 2025-01-30 and due to reach its primary completion in 2027-02. Interventions recorded: CT-P51 and EU-approved Keytruda.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06939595
- Phase: 3
- Setting: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Sponsor: Celltrion
- Enrolled: 225

## Sources

- ClinicalTrials.gov NCT06939595: https://clinicaltrials.gov/study/NCT06939595

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Celltrion](https://onco.cc/companies/celltrion/)

---
JSON: https://onco.cc/api/v1/entities/nct06939595.json